The medical device maker ended 48.40% below its 52-week high of $109.50, reached on 9 September.
Among peers, Abbott fell 1.46% to $89.46, Medtronic dropped 1.20% to $80.00 and Stryker declined 6.47% to $294.73.
Why is Boston Scientific's stock plunging in 2026 despite strong sales growth and major product approvals—are lawsuits and acquisitions spooking investors?
Could Boston Scientific's aggressive acquisitions and legal challenges threaten its ability to capitalize on booming medtech innovation and AI integration?